Pittenger & Anderson Inc. Lowers Position in Danaher Corporation $DHR

Pittenger & Anderson Inc. lessened its stake in shares of Danaher Corporation (NYSE:DHR) by 96.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,217 shares of the conglomerate’s stock after selling 36,956 shares during the period. Pittenger & Anderson Inc.’s holdings in Danaher were worth $241,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in DHR. WFA of San Diego LLC purchased a new position in Danaher during the second quarter valued at approximately $26,000. Howard Hughes Medical Institute bought a new stake in shares of Danaher during the 2nd quarter valued at $27,000. TruNorth Capital Management LLC purchased a new position in shares of Danaher during the 3rd quarter valued at $28,000. Red Tortoise LLC lifted its stake in shares of Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after buying an additional 98 shares in the last quarter. Finally, Tripletail Wealth Management LLC bought a new position in Danaher in the 3rd quarter worth $31,000. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares of the company’s stock, valued at $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 30,248 shares of company stock worth $6,609,663. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on DHR shares. Robert W. Baird set a $251.00 price objective on Danaher in a research report on Thursday. Redburn Partners set a $220.00 target price on Danaher in a research note on Wednesday, October 8th. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Morgan Stanley started coverage on shares of Danaher in a report on Monday, December 1st. They set an “overweight” rating and a $270.00 price objective for the company. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Danaher in a report on Monday, December 29th. Twenty research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $252.32.

Danaher Trading Down 0.4%

DHR stock opened at $218.82 on Friday. The firm has a fifty day moving average price of $230.60 and a 200 day moving average price of $213.96. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $242.80. The firm has a market cap of $154.56 billion, a PE ratio of 43.42, a price-to-earnings-growth ratio of 3.12 and a beta of 0.89. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.10 and a current ratio of 1.87.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09. Danaher had a net margin of 14.71% and a return on equity of 10.81%. The company had revenue of $6.84 billion for the quarter, compared to the consensus estimate of $6.79 billion. During the same quarter in the prior year, the firm earned $2.14 earnings per share. Danaher’s revenue was up 4.6% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. Sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 30th. Investors of record on Friday, December 26th were given a $0.32 dividend. The ex-dividend date was Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is currently 25.40%.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q4 results beat on EPS and management set FY2026 EPS guidance of $8.35–$8.50, which is above many street estimates and supports upside to earnings expectations. Danaher (DHR) Tops Q4 Earnings Estimates, Issues Solid 2026 Outlook
• Positive Sentiment: JPMorgan raised its price target to $275 and kept an overweight rating, signaling continued bullish sentiment among some large sell‑side shops. Benzinga
• Positive Sentiment: Molecular Devices (a Danaher business) announced a partnership to expand automated, AI‑ready research solutions — a product/market development that supports longer‑term growth in lab automation and software‑enabled sales. Molecular Devices Expands Access to Automated, AI-Ready Research Solutions
• Neutral Sentiment: Goldman Sachs trimmed its target slightly to $265 but maintained a buy rating, a modest calibration that still implies material upside but signals some caution. MarketScreener
• Neutral Sentiment: Earnings call transcripts and highlights show management emphasizing free cash flow and balance sheet strength, but a cautious tone on near‑term demand. These details provide context but are not unambiguously positive or negative. Danaher (DHR) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Market commentary and headlines framed the report as “in‑line” on sales and cautioned investors that the post‑earnings dip may not be a good buying opportunity, which likely amplified selling pressure. Danaher Stock Plunge Does Not Represent A Good Entry Point
• Negative Sentiment: Despite the EPS beat, some outlets highlighted the stock drop after an essentially in‑line revenue/outlook, reinforcing bearish sentiment in the short term. Danaher drops after in-line earnings outlook
• Negative Sentiment: Valuation is elevated (P/E ~43) versus historical averages, which can make the stock more sensitive to any guidance softness or mixed indicators.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.